News IDEXX Laboratories, Inc.

Stocks

IDXX

US45168D1046

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 21:00:00 23/10/2026 BST			5-day change	1st Jan Change
560.38 ^USD	-1.13%		+0.00%	-17.17%

10-20	Jefferies Adjusts Price Target on IDEXX Laboratories to $705 From $795	MT
10-16	JPMorgan Adjusts Price Target on IDEXX Laboratories to $750 From $775	MT

All News

Mentions Relevance

10-20	Jefferies Adjusts Price Target on IDEXX Laboratories to $705 From $795	MT
10-16	JPMorgan Adjusts Price Target on IDEXX Laboratories to $750 From $775	MT
10-12	KeyBanc Initiates IDEXX Laboratories at Sector Weight	MT
10-01	IDEXX Laboratories to Release 2026 Third Quarter Financial Results	BU
09-30	IDEXX Laboratories Acquires Veterinary AI Platform CoVetAI	MT
09-17	IDEXX Laboratories Adds Taeniid Tapeworm Detection to Parasite Testing Platform	MT
09-17	IDEXX Laboratories Expands Faecal DX Antigen Testing Platform in the United Kingdom with Taeniid Tapeworm Detection	CI
09-17	IDEXX Expands Faecal Dx Antigen Testing Platform in the United Kingdom with Taeniid Tapeworm Detection	BU
09-16	IDEXX Laboratories, Inc. acquired CoVetAI Inc.	CI
09-16	IDEXX Laboratories Acquires Veterinary AI Software Firm CoVetAI	MT
09-16	IDEXX Laboratories Acquires CoVetAI to Advance Veterinary Workflow Intelligence	BU
09-14	IDEXX Laboratories, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-14-2026 10:45 AM
08-31	IDEXX Laboratories to Participate in Morgan Stanley 24th Annual Global Healthcare Conference	BU
08-18	IDEXX Laboratories, Inc. - Analyst/Investor Day
08-11	IDEXX Laboratories Launches Catalyst proBNP Test for In-Clinic Cardiac Disease Assessment	MT
08-11	IDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP Test	BU
08-11	Idexx Laboratories Launches Catalyst Probnp Test for Cardiac Assessment in Cats and Dogs	CI
08-11	Barclays Adjusts Price Target on IDEXX Laboratories to $710 From $800, Keeps Overweight Rating	MT
08-05	Jefferies Adjusts Price Target on IDEXX Laboratories to $795 From $792	MT
08-05	Citigroup Adjusts Price Target on IDEXX Laboratories to $670 From $650	MT
08-05	UBS Adjusts Price Target on IDEXX Laboratories to $670 From $620, Maintains Neutral Rating	MT
08-04	IDEXX Laboratories : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)	PU
08-04	Tranche Update on IDEXX Laboratories, Inc.'s Equity Buyback Plan announced on August 13, 1999.	CI
08-04	Idexx Laboratories, Inc. Updates Earnings Guidance for 2026	CI
08-04	IDEXX Laboratories, Inc., Q2 2026 Earnings Call, Aug 04, 2026